Immunocore has entered into multi-target discovery partnerships with Genentech, GlaxoSmithKline and AstraZeneca (MedImmune), to develop novel cancer therapies using Immunocore’s ImmTAC technology. A fourth partnership, with Eli Lilly, includes a co-development option in addition to ImmTAC co-discovery.
In addition to their use as monotherapies, due to their excellent safety profile, ImmTAC molecules are expected to prove to be valuable in combination with other immunotherapy mechanisms leading to synergistic efficacies and hence potentially improved overall survival and response rates. For example, ImmTAC molecules have the potential to drive circulating T cells to infiltrate tumours whilst checkpoint inhibitors restrict the mechanisms cancers use to try and suppress T cell activity, leading to a synergistic effect.
Immunocore has entered into a strategic collaboration with MedImmune, the biologics division of AstraZeneca, to combine IMCgp100 with two checkpoint agents, MEDI4736 (anti-PD-L1) and tremelimumab (anti-CTLA4) in order to treat late stage cutaneous melanoma. More recently, Immunocore also entered into an immunotherapy-based clinical trial collaboration with Lilly to explore the utility of IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of metastatic cutaneous and uveal melanomas respectively. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead programme, IMCgp100, for the treatment of uveal melanoma.
Immunocore has an interest in relevant technologies and will be seeking to license and acquire technologies to enhance existing programmes and create new areas of opportunity.
For further information about partnering and licensing opportunities please contact Immunocore’s Business Development group at email@example.com.